Belgium · Delayed Price · Currency is EUR | Market Cap | 41.55B |
| Revenue (ttm) | 2.66B |
| Net Income (ttm) | 1.09B |
| Shares Out | 61.20M |
| EPS (ttm) | 15.96 |
| PE Ratio | 42.53 |
| Forward PE | 38.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,718 |
| Average Volume | 158,010 |
| Open | 687.00 |
| Previous Close | 679.00 |
| Day's Range | 684.20 - 692.60 |
| 52-Week Range | 456.60 - 692.60 |
| Beta | 0.04 |
| RSI | 73.41 |
| Earnings Date | Oct 30, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
Morgan Stanley Raises Price Target for ARGX to $1040 While Maintaining Overweight Rating | ARGX ...
Morgan Stanley Raises Price Target for ARGX to $1040 While Maintaining Overweight Rating | ARGX Stock News
INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of ...
Price Over Earnings Overview: argenx
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08% , but in the past year, went u...
Guggenheim Reiterates Buy Rating for ARGX with Target Price of $1070 | ARGX Stock News
Guggenheim Reiterates Buy Rating for ARGX with Target Price of $1070 | ARGX Stock News
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a s...
argenx SE - Special Call
Argenx SE (ARGX) Discusses On R&D Spotlight | Pioneering MuSK Biology With ARGX-119 Conference Transcript
argenx SE (ARGX) Special Call - Slideshow
2025-09-16. The following slide deck was published by argenx SE in conjunction with this event.
ARGX Quantitative Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjami...
argenx: Bullish On This R&D Focused Biotech Stock
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel ...
Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns
Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 26.74%. Currently, argenx has a market capitalization of...
Is argenx Gaining or Losing Market Support?
argenx's (NYSE: ARGX) short percent of float has fallen 4.11% since its last report. The company recently reported that it has 1.81 million shares sold short , which is 3.27% of all regular shares th...
Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News
B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News
argenx to Present at Upcoming Investor Conferences
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Argenx saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx SE (NASDAQ: ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod...
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)...
Argenx Tops Buy Point On Bullish Study, 850 Price Target
Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart.
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Argenx reported positive Phase 3 Vyvgart data in ... Full story available on Benzinga.com
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegati...